Liminatus Pharma, Inc. (LIMNW) Stock Price & Analysis
Liminatus Pharma, Inc. (LIMNW) closed at USD 0.04 on Thursday, October 15, 2026, down 8.05% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.04; the Oct 15, 2026 session ranged USD 0.04–0.04 on volume of 213 shares. Market capitalization is —, with a 52-week range of USD 0.04–0.04 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LIMNW.md
Key facts (LIMNW)
- Analysts: None.
Analysts (LIMNW)
Consensus None.
Key Statistics (as of October 16, 2026 at 05:49 UTC)
| Price | USD 0.04 |
|---|---|
| Change | ▼ 8.05% (down) |
| Previous Close | USD 0.04 |
| Open | USD 0.04 |
| Day Range | USD 0.04 – 0.04 |
| 52-Week Range | USD 0.04 – 0.04 |
| Volume | 213 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (LIMNW)
Wall Street analysts rate LIMNW "None", per Nexqual as of October 16, 2026 at 05:49 UTC.
| Consensus Rating | None |
|---|
Earnings (LIMNW)
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Financials & Fundamentals (LIMNW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 4.8 |
| Current Ratio | 1.12 |
| Total Cash | $3.02M |
| Total Debt | $1.44M |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Financial Health Score (LIMNW)
Nexqual rates Liminatus Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Critical — $3M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$4M (TTM) |
| Efficiency | Mixed — No data |
Ownership (LIMNW)
| Float | 1.02M |
|---|
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Leadership (LIMNW)
Liminatus Pharma, Inc. is led by Chris Kim J.D., L.L.M. (age 65), CEO, Chairman & President, per Nexqual as of October 16, 2026 at 05:49 UTC.
| CEO, Chairman & President | Chris Kim J.D., L.L.M. (age 65) |
|---|---|
| Chief Financial Officer | Scott Dam (age 46) |
| Chief Technology Officer & Member of Scientific Advisory Board | Beom Kyu Choi (age 53) |
Major Backers & Investors (LIMNW)
Notable institutional backers of Liminatus Pharma, Inc. include Aristeia Capital, LLC, Linden Advisors LP, Saba Capital Management, L.P., according to Nexqual as of October 16, 2026 at 05:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Aristeia Capital, LLC | 4.13% |
| Linden Advisors LP | 3.47% |
| Saba Capital Management, L.P. | 3.38% |
| Moore Capital Management, LP | 1.62% |
| Polar Asset Management Partners Inc. | 1.59% |
| MMCAP International, Inc. SPC | 1.44% |
| Shaw D.E. & Co., Inc. | 1.08% |
| Blue Owl Capital Holdings LP | 0.65% |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIMN | Liminatus Pharma, Inc. | USD 3.21 | ▼ 5.87% |
| KIDZW | Classover Holdings, Inc. Warran | USD 0.01 | ▲ 1.27% |
| GRMLW | Greenland Mines Ltd | USD 0.68 | ▲ 1.23% |
| CYCUW | Cycurion, Inc. Warrant | USD 0.03 | ▲ 39.9% |
| DAICW | CID HoldCo, Inc. Warrants | USD 0.01 | ▲ 55.38% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt